Catalio Capital Management | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Catalio Capital Management/Activity

Catalio Capital Management Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Milestone

Portfolio company Superluminal Medicines closed an oversubscribed $60M Series B to advance its AI-powered small-molecule obesity discovery engine.

Superluminal Medicines

Superluminal Medicines Catalio Capital Management

x.comSEP 11, 2026

SEP 11, 2026

News

Named again to TIME's list of America's Top Venture Capital Firms.

TIME America's Top Venture Capital Firms 2026

Catalio Capital Management

x.comAUG 23, 2026

AUG 23, 2026

Podcast

Co-Founder & Managing Partner George Petrocheilos discussed the Catalio journey on the BioVenture VoiCes podcast.

George Petrocheilos on BioVenture VoiCes

Catalio Capital Management

x.comAUG 11, 2026

AUG 11, 2026

3 investments· JUL 2026 – AUG 2026Show all

Investment

Participated in Ratio Therapeutics' $70M Series C alongside Eli Lilly, Bristol Myers Squibb, and Duquesne.

Ratio Therapeutics

Ratio Therapeutics Catalio Capital Management

x.comAUG 1, 2026

AUG 1, 2026

Investment

Co-led Claris Bio's $118M Series B alongside Samsara to advance treatment for limbal stem cell deficiency.

Claris Bio

Claris Bio Catalio Capital Management

x.comJUL 29, 2026

JUL 29, 2026

Investment

Supported Entera Bio's oversubscribed $275M PIPE financing to fund its Phase 3 program for EB613.

Entera Bio

Entera Bio Catalio Capital Management

x.comJUL 28, 2026

JUL 28, 2026

3 exits· JUN 2026 – JUL 2026Show all

Exit

Portfolio company Atai Life Sciences was acquired by Eli Lilly for $3.8B; Catalio co-led Atai's 2020 Series C.

atai Life Sciences

atai Life Sciences Catalio Capital Management

x.comJUL 21, 2026

JUL 21, 2026

Exit

Portfolio company Kardigan completed a $460M IPO on Nasdaq under ticker KARD.

Kardigan

Kardigan Catalio Capital Management

x.comJUN 26, 2026

JUN 26, 2026

Exit

Portfolio company Parabilis Medicines completed a record-setting $670M IPO on Nasdaq under ticker PBLS, the largest in the sector's history.

Parabilis Medicines (formerly FogPharma)

Parabilis Medicines (formerly FogPharma)Catalio Capital Management

x.comJUN 11, 2026

JUN 11, 2026

New Fund

Raised over $400M for its fourth venture fund to invest in innovative healthcare companies.

Catalio Nexus Fund IV

Catalio Capital Management

businesswire.comJUL 1, 2025

JUL 1, 2025